The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Appetite-Suppressant Drugs and the Risk of Primary Pulmonary Hypertension
Open accessAbstract
BACKGROUND: Recently, a cluster of patients was observed in France in whom primary pulmonary hypertension developed in patients exposed to derivatives of fenfluramine in appetite suppressants (anorexic agents), which are used for weight control. We investigated the potential role of anorexic agents and other suspected risk factors for primary pulmonary hypertension. METHODS: In a case-control study, we assessed 95 patients with primary pulmonary hypertension from 35 centers in France, Belgium, the United Kingdom, and the Netherlands and 355 controls recruited from general practices and matched to the patients' sex and age. RESULTS: The use of anorexic drugs (mainly derivatives of fenfluramine) was associated with an increased risk of primary pulmonary hypertension (odds ratio with any anorexic-drug use, 6.3; 95 percent confidence interval, 3.0 to 13.2). For the use of anorexic agents in the preceding year, the odds ratio was 10.1 (95 percent confidence interval, 3.4 to 29.9). When anorexic drugs were used to a total of more than three months, the odds ratio was 23.1 (95 percent confidence interval, 6.9 to 77.7). We also confirmed an association with several previously identified risk factors: a family history of pulmonary hypertension, infection with the human immunodeficiency virus, cirrhosis, and use of cocaine or intravenous drugs. CONCLUSIONS: The use of anorexic drugs was associated with the development of primary pulmonary hypertension. Active surveillance for this disease should be considered, particularly since their use is expected to increase in the near future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Certainly, starvation, very-low-calorie diets, liquid protein diets, and obesity surgeries have been associated with prolongation of the QTc interval and increased risk of malignant dysrhythmias (1), and various pharmacologic agents have either limited efficacy or considerable toxicity (70 -72).”
From Obesity and Cardiovascular Disease (2009) · cites this paper as [71]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Primary Pulmonary Hypertension
Rich, S., DANTZKER, D. R., AYRES, S. M., BERGOFSKY, E. H., BRUNDAGE, B. H., Detre, K. M., FISHMAN, A. P., GOLDRING, R. M., GROVES, B. M., KOERNER, S. K., et al. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-2-216 · Cited by 2,027
Self-citationThe Effect of High Doses of Calcium-Channel Blockers on Survival in Primary Pulmonary Hypertension
Rich, S., Kaufmann, E., & Levy, P. S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199207093270203 · Cited by 1,558
Self-citationTreatment of Primary Pulmonary Hypertension with Continuous Intravenous Prostacyclin (Epoprostenol)
Rubin, L. J., Mendoza, J., Hood, M., McGoon, M., Barst, R., Williams, W. B., Diehl, J. H., Crow, J., & Long, W. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-7-485 · Cited by 701
Increased plasma serotonin in primary pulmonary hypertension
Hervé, P., Launay, J., Scrobohaci, M.-L., Brenot, F., Simonneau, G., PETITPRETZ, P., Poubeau, P., Cerrina, J., Duroux, P., & Drouet, L. O. (1995) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)80156-9 · Cited by 557
Self-citationHadengue, A., Benhayoun, M. K., Lebrec, D., & Benhamou, J. (1991) · Gastroenterology · doi:10.1016/0016-5085(91)90225-a · Cited by 497
Primary Pulmonary Hypertension and Cirrhosis: Are They Related?
McDonnell, P. J., Toye, P. A., & Hutchins, G. M. (1983) · American Review of Respiratory Disease · doi:10.1164/arrd.1983.127.4.437 · Cited by 318
Primary Pulmonary Hypertension
Rubin, L. J. (1993) · CHEST Journal · doi:10.1378/chest.104.1.236 · Cited by 308
Primary pulmonary hypertension and fenfluramine use.
Brénot, F., Hervé, P., PETITPRETZ, P., Parent, F., Duroux, P., & Simonneau, G. (1993) · Heart · doi:10.1136/hrt.70.6.537 · Cited by 247
Self-citationPETITPRETZ, P., Brénot, F., Azarian, R., Parent, F., Rain, B., Hervé, P., & Simonneau, G. (1994) · Circulation · doi:10.1161/01.cir.89.6.2722 · Cited by 238
Self-citationPulmonary hypertension and fenfluramine
Douglas, J. G., Munro, J., KITCHIN, A. H., Muir, A. L., & Proudfoot, A. T. (1981) · BMJ · doi:10.1136/bmj.283.6296.881 · Cited by 180
Research works printed but not linked: 3
- Gurtner HP, 1985, Cor Vasa, 27, 160
- Michelakis ED, 1995, Am J Respir Crit Care Med, 151, A725
- Russel LA, 1992, Am Rev Respir Dis, 145, A717
Cited by
Sorted by citations
Items 401–500 of 999
Grimaldi‐Bensouda, L., Guern, V. L., Koné‐Paut, I., Aubrun, E., Fain, O., Ruel, M., Machet, L., Viallard, J., Magy-Bertrand, N., Daugas, É., et al. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38429 · Cited by 38
Self-citationTribouilloy, C. M., Ruşinaru, D., Maréchaux, S., Jeu, A., Éderhy, S., Donal, E., Réant, P., Arnalsteen, E., Boulanger, J., Ennezat, P., et al. (2012) · Circulation · doi:10.1161/circulationaha.112.111260 · Cited by 38
Inhibition of gut- and lung-derived serotonin attenuates pulmonary hypertension in mice
Abid, S., Houssaini, A., Chevarin, C., Marcos, É., Tissot, C.-M., Gary‐Bobo, G., Wan, F., Mouraret, N., Amsellem, V., Dubois‐Randé, J., et al. (2012) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00049.2012 · Cited by 38
Johansen, A. K. Z., Dean, A., Morecroft, I., Hood, K. Y., Nilsen, M., Loughlin, L., Anagnostopoulou, A., Touyz, R. M., White, K., & MacLean, M. R. (2016) · Pulmonary Circulation · doi:10.1086/685023 · Cited by 38
Hong, Z., Smith, A. J., Archer, S. L., Wu, X.-C., Nelson, D. P., Peterson, D. A., Johnson, G. J., & Weir, Ε. K. (2005) · Circulation · doi:10.1161/circulationaha.105.556704 · Cited by 38
Cardiovascular Effects of Noncardiovascular Drugs
Raj, S. R., Stein, C. M., Saavedra, P. J., & Roden, D. M. (2009) · Circulation · doi:10.1161/circulationaha.107.728576 · Cited by 38
ABSENCE OF HYPERHOMOCYSTEINEMIA IN TEN PATIENTS WITH PRIMARY PULMONARY HYPERTENSION
Zighetti, M. L., Cattaneo, M., Falcón, C., Lombardi, R., Harari, S. A., Savoritto, S., & Mannucci, P. M. (1997) · Thrombosis Research · doi:10.1016/s0049-3848(97)00013-3 · Cited by 38
Histologic Changes in Three Explanted Native Cardiac Valves Following Use of Fenfluramines
Steffee, C. H., Singh, H. K., & Chitwood, W. R. (1999) · Cardiovascular Pathology · doi:10.1016/s1054-8807(99)00019-8 · Cited by 38
Current Management of Primary Pulmonary Hypertension
Klings, E. S., & Farber, H. W. (2001) · Drugs · doi:10.2165/00003495-200161130-00005 · Cited by 38
Grimaldi‐Bensouda, L., Rossignol, M., Aubrun, E., Kerri, N. E., Jacques, B., & Lucien, A. (2010) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1952 · Cited by 37
Diagnosis and Management of Pulmonary Arterial Hypertension
Houtchens, J., Martin, D., & Klinger, J. R. (2011) · Pulmonary Medicine · doi:10.1155/2011/845864 · Cited by 37
Fornaro, M., Solmi, M., Perna, G., Berardis, D. D., Veronese, N., Orsolini, L., Ganança, L., & Stubbs, B. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s109637 · Cited by 41
Risks associated with herbal slimming remedies
Corns, C. M., & Metcalfe, K. (2002) · The Journal of the Royal Society for the Promotion of Health · doi:10.1177/146642400212200407 · Cited by 37
Badesch, D. B., Bodin, F., Channick, R. N., Frost, A., Rainisio, M., Robbins, I. M., Roux, S., Rubin, L. J., Simonneau, G., Sitbon, O., et al. (2002) · Current Therapeutic Research · doi:10.1016/s0011-393x(02)80029-7 · Cited by 37
Self-citationThe Case for Medical Management of Obesity: A Call for Increased Physician Involvement
Rippe, J. M. (1998) · Obesity Research · doi:10.1002/j.1550-8528.1998.tb00685.x · Cited by 38
Guías de Práctica Clínica sobre el diagnóstico y tratamiento de la hipertensión arterial pulmonar
el diagnóstico, G. D. T. S., & de Cardiología, T. D. L. H. A. P. D. L. S. E. (2005) · Revista Española de Cardiología · doi:10.1157/13074846 · Cited by 37
Diagnosis and evaluation of pulmonary hypertension.
Budev, M. M., Arroliga, A. C., & Jennings, C. A. (2003) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.70.suppl_1.s9 · Cited by 37
The Case-Population Study Design
Théophile, H., Laporte, J., Moore, N. D., Martin, K., & Bégaud, B. (2011) · Drug Safety · doi:10.2165/11592140-000000000-00000 · Cited by 36
Self-citationUndem, C., Rios, E. J., Maylor, J., & Shimoda, L. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046303 · Cited by 36
Hamal, K. R., Wideman, R. F., Jr., Anthony, N. B., & Erf, G. F. (2009) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00451.2009 · Cited by 36
Ven, F. L., Tribouilloy, C., Habib, G., Gueffet, J.-P., Maréchaux, S., Eicher, J., Blanchard-Lemoine, B., Rousseau, J., Henon, P., Jobic, Y., et al. (2010) · European Journal of Echocardiography · doi:10.1093/ejechocard/jeq172 · Cited by 36
Drugs induced pulmonary arterial hypertension
Seferian, A., Chaumais, M., Savale, L., Günther, S., Tubert‐Bitter, P., Humbert, M. J. C., & Montani, D. (2013) · La Presse Médicale · doi:10.1016/j.lpm.2013.07.005 · Cited by 36
Palamara, K., Mogul, H. R., Peterson, S. J., & Frishman, W. H. (2006) · Cardiology in Review · doi:10.1097/01.crd.0000233903.57946.fd · Cited by 36
Rabinovitch, M. (2001) · Journal of Clinical Investigation · doi:10.1172/jci14205 · Cited by 36
Fenfluramine-induced pulmonary vasoconstriction: role of serotonin receptors and potassium channels
Bělohlávková, S., Šimák, J., Kokešová, A., Hniličková, O., & Hampl, V. (2001) · Journal of Applied Physiology · doi:10.1152/jappl.2001.91.2.755 · Cited by 36
Modern Obesity Pharmacotherapy: Weighing Cardiovascular Risk and Benefit
Cunningham, J. W., & Wiviott, S. D. (2014) · Clinical Cardiology · doi:10.1002/clc.22304 · Cited by 35
Characteristics of Patients with Pulmonary Venoocclusive Disease Awaiting Transplantation
Wille, K. M., Sharma, N., Kulkarni, T., Lammi, M. R., Barney, J. B., Bellot, S., Cantor, R. S., Naftel, D. C., Diaz‐Guzman, E., & McGiffin, D. C. (2014) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201408-354oc · Cited by 35
Drug-induced pulmonary arterial hypertension: a primer for clinicians and scientists
Orcholski, M. E., Yuan, K., Rajasingh, C. M., Tsai, H., Shamskhou, E. A., Dhillon, N. K., Voelkel, N. F., Zamanian, R. T., & Pérez, V. D. J. (2018) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00553.2017 · Cited by 35
Advances in the Treatment of Drug-Resistant Pediatric Epilepsy
Gonzalez‐Giraldo, E., & Sullivan, J. E. (2020) · Seminars in Neurology · doi:10.1055/s-0040-1702941 · Cited by 40
Dexfenfluramine as a mitogen signals through the formation of superoxide anion
Lee, S.-L., Wang, W.-W., & Fanburg, B. L. (2001) · The FASEB Journal · doi:10.1096/fj.00-0431fje · Cited by 35
Diagnosis and management of pulmonary hypertension over the past 100 years
van Wolferen, S. A., Grünberg, K., & Noordegraaf, A. V. (2007) · Respiratory Medicine · doi:10.1016/j.rmed.2006.11.022 · Cited by 35
Mild hypoxia causes severe pulmonary hypertension in fawn-hooded but not in Tester Moriyama rats
Nagaoka, T., Muramatsu, M., Sato, K., McMurtry, I. F., Oka, M., & Fukuchi, Y. (2001) · Respiration Physiology · doi:10.1016/s0034-5687(01)00217-1 · Cited by 35
Evaluating Drug Effects in the Post-Vioxx World
Avorn, J. (2006) · Circulation · doi:10.1161/circulationaha.106.625749 · Cited by 38
Pulmonary Arterial Hypertension
Michelakis, E. D. (2014) · Circulation Research · doi:10.1161/circresaha.115.301132 · Cited by 34
Evaluation of Selective 5-HT 2C Agonists in Acute Seizure Models
Silenieks, L. B., Carroll, N. K., Niekerk, A. V., Niekerk, E. V., Taylor, C., Upton, N., & Higgins, G. A. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00739 · Cited by 37
Epilepsy in Dravet Syndrome—Current and Future Therapeutic Opportunities
Gao, C., Pielas, M., Jiao, F., Mei, D., Wang, X., Kotulska, K., & Jóźwiak, S. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12072532 · Cited by 37
Rasmussen, V. G., Østergaard, K., Dupont, E., & Poulsen, S. H. (2011) · Movement Disorders · doi:10.1002/mds.23470 · Cited by 34
Toxin-Induced Cardiovascular Failure
Jang, D. H., Spyres, M. B., Fox, L., & Manini, A. F. (2013) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2013.10.003 · Cited by 34
Diet Drug-Related Cardiac Valve Disease: The Mayo Clinic Echocardiographic Laboratory Experience
Teramae, C. Y., Connolly, H. M., Grogan, M. A., & Miller, F. A. (2000) · Mayo Clinic Proceedings · doi:10.4065/75.5.456 · Cited by 34
Endothelial Dysfunction Providing the Basis for the Treatment of Pulmonary Hypertension
HIGENBOTTAM, T. W., & Laude, E. A. (1998) · CHEST Journal · doi:10.1378/chest.114.1_supplement.72s · Cited by 34
Self-citationŻółkowska, D., Baumann, M. H., & Rothman, R. B. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.132654 · Cited by 33
Prothrombotic mechanisms in primary pulmonary hypertension
Farber, H. W., & Loscalzo, J. (1999) · Journal of Laboratory and Clinical Medicine · doi:10.1016/s0022-2143(99)90094-x · Cited by 33
Recent Advances in Pharmacologic Treatments of Drug-Resistant Epilepsy: Breakthrough in Sight
Klein, P., Friedman, D. J., & Kwan, P. (2024) · CNS Drugs · doi:10.1007/s40263-024-01130-y · Cited by 32
Fatal pulmonary arterial hypertension associated with phenylpropanolamine exposure
Barst, R. J., & Abenhaim, L. (2004) · Heart · doi:10.1136/hrt.2004.036491 · Cited by 32
Self-citationDietary supplements for obesity
Bonetti, G., Herbst, K. L., Donato, K., Dhuli, K., Kiani, A. K., Aquilanti, B., Velluti, V., Matera, G., Iaconelli, A., & Bertelli, M. (2022) · Journal of preventive medicine and hygiene · doi:10.15167/2421-4248/jpmh2022.63.2s3.2757 · Cited by 39
Debelle, F., Nortier, J., Arlt, V. M., Prez, E. D., Vienne, A. R., Salmon, I. J., Phillips, D. H., Deschodt-Lanckman, M. M., & Vanherweghem, J. (2003) · Archives of Toxicology · doi:10.1007/s00204-003-0438-y · Cited by 32
The Effects of Drugs Used to Treat Obesity on the Autonomic Nervous System
Hirsch, J., Mackintosh, R. M., & Aronne, L. J. (2000) · Obesity Research · doi:10.1038/oby.2000.26 · Cited by 32
Appetite suppressants and valvular heart disease in a population-based sample: the HyperGEN study
Palmieri, V., Arnett, D. K., Roman, M. J., Liu, J. E., Bella, J. N., Oberman, A., Kitzman, D. W., Hopkins, P. N., Morgan, D., SIMONE, G. D., et al. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01123-3 · Cited by 32
Long‐Term Drug Treatment of Obesity in a Private Practice Setting
Atkinson, R. L., Blank, R. C., Schumacher, D., Dhurandhar, N. V., Ritch, D. L., Chan, E. S. Y., & Rieg, T. S. (1997) · Obesity Research · doi:10.1002/j.1550-8528.1997.tb00579.x · Cited by 32
Hemodynamic Responses of Broiler Pulmonary Vasculature to Intravenously Infused Serotonin
Chapman, M. E., & Wideman, R. F., Jr. (2002) · Poultry Science · doi:10.1093/ps/81.2.231 · Cited by 32
Present and future pharmacological approaches
Finer, N. (1997) · British Medical Bulletin · doi:10.1093/oxfordjournals.bmb.a011620 · Cited by 32
Proietto, J., Fam, B. C., Ainslie, D. A., & Thorburn, A. W. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.6.1317 · Cited by 32
New therapies for pulmonary arterial hypertension: an update on current bench to bedside translation
Dewachter, L., Dewachter, C., & Naeije, R. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543781003727099 · Cited by 31
Impact of Antiseizure Medications on Appetite and Weight in Children
Buraniqi, E., Dabaja, H., & Wirrell, E. C. (2022) · Pediatric Drugs · doi:10.1007/s40272-022-00505-2 · Cited by 33
Reeve, H. L., Archer, S. L., Soper, M., & Weir, Ε. K. (1999) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.1999.277.3.l662 · Cited by 31
Update on the Pharmacotherapy of Obesity
Cerulli, J., Lomaestro, B. M., & Malone, M. (1998) · Annals of Pharmacotherapy · doi:10.1345/aph.17039 · Cited by 31
Sills, G. J. (2023) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864231191000 · Cited by 30
Physiological process of fat loss
El-Zayat, S. R., Sibaii, H., & El-Shamy, K. A. (2019) · Bulletin of the National Research Centre/Bulletin of the National Research Center · doi:10.1186/s42269-019-0238-z · Cited by 40
Novel Experimental Therapies for Treatment of Pulmonary Arterial Hypertension
Zolty, R. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s236743 · Cited by 32
Choi, H., Baeck, S., Jang, M., Lee, S., Choi, H., & Chung, H. (2011) · Forensic Science International · doi:10.1016/j.forsciint.2011.02.011 · Cited by 30
Reeve, H. L., Nelson, D. P., Archer, S. L., & Weir, Ε. K. (1999) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.1999.276.2.l213 · Cited by 30
da Rocha, A. J., Maia, A. C. M., da Silva, C. J., Braga, F. T., Ferreira, N. P. D. F., Barsottini, O. G. P., & Ferraz, H. B. (2006) · Movement Disorders · doi:10.1002/mds.21229 · Cited by 30
Birth weight and the Metabolic Syndrome: thrifty phenotype or thrifty genotype?
Stern, M. P., Bartley, M., Duggirala, R., & Bradshaw, B. (2000) · Diabetes/Metabolism Research and Reviews · doi:10.1002/(sici)1520-7560(200003/04)16:2 · Cited by 65
Precision Medicine in Obesity and Type 2 Diabetes: The Relevance of Early-Life Exposures
Estampador, A. C., & Franks, P. W. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2017.273540 · Cited by 32
Garbe, E., & Suissa, S. (2005) · Springer eBooks · doi:10.1007/978-3-540-26577-1_31 · Cited by 29
Delayed Onset of Pulmonary Hypertension Associated With an Appetite Suppressant, Mazindol
Hagiwara, M., Tsuchida, A., Hyakkoku, M., Nishizato, K., Asai, T., Nozawa, Y., Tsuchihashi, K., & Shimamoto, K. (2000) · Japanese Circulation Journal-english Edition · doi:10.1253/jcj.64.218 · Cited by 29
Hair analysis for fenfluramine and norfenfluramine as biomarkers for N-nitrosofenfluramine ingestion
Kaddoumi, A., Wada, M., Nakashima, M. N., & Nakashima, K. (2004) · Forensic Science International · doi:10.1016/j.forsciint.2004.03.018 · Cited by 29
Plötzlicher Tod im Erwachsenenalter
Püschel, K., & Kernbach-Wighton, G. (2004) · Springer eBooks · doi:10.1007/978-3-662-45345-2_23 · Cited by 29
Obesity and insulin resistance in young people
Valente, A. M., Strong, W. B., & Sinaiko, A. R. (2001) · American Heart Journal · doi:10.1067/mhj.2001.117828 · Cited by 29
USE OF DRUGS IN THE TREATMENT OF OBESITY
Atkinson, R. L. (1997) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.17.1.383 · Cited by 29
Endoscopic vertical band gastroplasty with an endoscopic sewing machine
Awan, A. N., & Swain, C. P. (2002) · Gastrointestinal Endoscopy · doi:10.1067/mge.2002.120889 · Cited by 29
Michelakis, E. D., Weir, Ε. K., Nelson, D. P., Reeve, H. L., Tolarová, S., & Archer, S. L. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35220-6 · Cited by 29
para-Trifluoromethyl-methcathinone is an allosteric modulator of the serotonin transporter
Niello, M., Cintulová, D., Hellsberg, E., Jäntsch, K., Holy, M., Ayatollahi, L. H., Cozzi, N. V., Freissmuth, M., Sandtner, W., Ecker, G. F., et al. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.04.021 · Cited by 28
Role of the Aryl Hydrocarbon Receptor/ARNT/Cytochrome P450 System in Pulmonary Vascular Diseases
Kwapiszewska, G., Johansen, A. K. Z., Gomez‐Arroyo, J. G., & Voelkel, N. F. (2019) · Circulation Research · doi:10.1161/circresaha.119.315054 · Cited by 27
Primary pulmonary hypertension after amfepramone (diethylpropion) with BMPR2 mutation
Abramowicz, M. J., Haecke, P. V., DEMEDTS, M. G., & Delcroix, M. (2003) · European Respiratory Journal · doi:10.1183/09031936.03.00095303 · Cited by 28
Gene transfer and metabolic modulators as new therapies for pulmonary hypertension
Michelakis, E. D., Dyck, J. R. B., McMurtry, M. S., Wang, S., Wu, X., Moudgil, R., Hashimoto, K., Puttagunta, L., & Archer, S. L. (2001) · Advances in experimental medicine and biology · doi:10.1007/978-1-4757-3401-0_26 · Cited by 28
Ray, J. G. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.3.249 · Cited by 28
Kaddoumi, A., Nakashima, M. N., & Nakashima, K. (2001) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/s0378-4347(01)00368-1 · Cited by 28
Severe pulmonary hypertensive diseases: a perspective
Voelkel, N. F., & Tuder, R. M. (1999) · European Respiratory Journal · doi:10.1183/09031936.99.14612469 · Cited by 28
Supplemental Studies for Cardiovascular Risk Assessment in Safety Pharmacology: A Critical Overview
Picard, S., Goineau, S., Guillaume, P., Henry, J., Hanouz, J., & Rouet, R. (2011) · Cardiovascular Toxicology · doi:10.1007/s12012-011-9133-z · Cited by 28
Serotonin Signaling in Pulmonary Hypertension
deCaestecker, M. P. (2006) · Circulation Research · doi:10.1161/01.res.0000225927.04710.33 · Cited by 28
Obesity, Metabolic Syndrome and Disorders of Energy Balance
Han, J. C., & Weiss, R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-62520-3.00024-5 · Cited by 27
Occupational, environmental and iatrogenic lung disease
CORRIN, B., & Nicholson, A. G. (2011) · Elsevier eBooks · doi:10.1016/b978-0-7020-3369-8.00007-0 · Cited by 28
Misumi, K., Ogo, T., Ueda, J., Tsuji, A., Fukui, S., Konagai, N., Asano, R., & Yasuda, S. (2018) · Internal Medicine · doi:10.2169/internalmedicine.1523-18 · Cited by 27
Diagnosis and Management of Pulmonary Arterial Hypertension: Implications for Respiratory Care
Levine, D. J. (2006) · Respiratory Care · doi:10.4187/respcare.06510368 · Cited by 27
Standard Therapies for Pulmonary Arterial Hypertension
Alam, S., & Palevsky, H. I. (2007) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2006.12.003 · Cited by 27
Genetics and Immunogenetic Aspects of Primary Pulmonary Hypertension
Barst, R. J., & Loyd, J. E. (1998) · CHEST Journal · doi:10.1378/chest.114.3_supplement.231s · Cited by 27
Pharmacological Treatment of Obesity in Paediatric Patients
Daniels, S. R. (2001) · Pediatric Drugs · doi:10.2165/00128072-200103060-00001 · Cited by 27
Pulmonary arterial hypertension in women
Sanchez, O., Marié, E., Lerolle, U., Wermert, D., Israël‐Biet, D., & Meyer, G. (2010) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2009.12.001 · Cited by 26
New insights into the pathogenesis and treatment of primary pulmonary hypertension
Rudarakanchana, N. (2001) · Thorax · doi:10.1136/thorax.56.11.888 · Cited by 26
Epidemiology of Pulmonary Arterial Hypertension
Jiang, X., & Jing, Z. (2013) · Current Hypertension Reports · doi:10.1007/s11906-013-0397-5 · Cited by 26
Graf, S., Huber-Beckmann, R., Zorn, G., Lang, I., Kneussl, M., Binder, B., Huber, K., & Christ, G. (2001) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1616086 · Cited by 26
Primary pulmonary hypertension
Rich, S. (2000) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-000-0006-1 · Cited by 26
Self-citationEstrategias terapéuticas actuales en la hipertensión arterial pulmonar
Galiè, N., Palazzini, M., Leci, E., & Manes, A. (2010) · Revista Española de Cardiología · doi:10.1016/s0300-8932(10)70163-9 · Cited by 24
The love of a lifetime: 5-HT in the cardiovascular system
Watts, S. W. (2008) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.90676.2008 · Cited by 25
Mercurio, V., Bianco, A., Campi, G., Cuomo, A., Diab, N., Mancini, A., Parrella, P., Petretta, M., Hassoun, P. M., & Bonaduce, D. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180201095743 · Cited by 25
Weyer, C., & de Souza, C. J. (2000) · Drug Development Research · doi:10.1002/1098-2299(200010)51:2 · Cited by 16
Serotonin (5‐HT) Transporter Ligands Affect Plasma 5‐HT in Rats
Rothman, R. B., Żółkowska, D., & Baumann, M. H. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1432.042 · Cited by 21
Kaddoumi, A., Nakashima, M. N., Maki, T., Matsumura, Y., Nakamura, J., & Nakashima, K. (2003) · Journal of Chromatography B · doi:10.1016/s1570-0232(03)00231-9 · Cited by 25
Dexfenfluramine protects against pulmonary hypertension in rats
Mitani, Y., Mutlu, A., Russell, J. C., Brindley, D. N., DeAlmeida, J., & Rabinovitch, M. (2002) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00500.2002 · Cited by 25
Metadata
- Authors
- Abenhaim, L., Moride, Y., Brenot, F., Rich, S., Benichou, J., Kurz, X., Higenbottam, T., Oakley, C., Wouters, E., Aubier, M., Simonneau, G., & Bégaud, B.
- Affiliations
- Jewish General Hospital (CA)
- Hôpital Antoine-Béclère (FR)
- University of Illinois Chicago (US)
- Centre Hospitalier Universitaire de Liège (BE)
- University of Sheffield (GB)
- Hammersmith Hospital (GB)
- Maastricht University Medical Centre (NL)
- Hôpital Bichat-Claude-Bernard (FR)
- Hôpital Pellegrin (FR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1996-08-29
- Volume
- 335
- Issue
- 9
- Pages
- 609-616
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2329065056
- Cited by
- 1,162
- References
- 26
- Citations by year
- 2026: 7 · 2025: 23 · 2024: 22 · 2023: 21 · 2022: 22 · 2021: 16 · 2020: 16 · 2019: 20 · 2018: 27 · 2017: 29 · 2016: 18 · 2015: 30 · 2014: 27 · 2013: 39 · 2012: 34
- FWCI
- 71.92
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- idiopathic pulmonary arterial hypertension, appetite suppressants, drug-induced pulmonary hypertension, risk factors, HIV infection, liver cirrhosis, cocaine use, intravenous drug use, weight management
- MeSH terms
- Adolescent, Adult, Aged, Appetite Depressants, Belgium, Female, Fenfluramine, France, United Kingdom, Heart Function Tests, Hemodynamics, Humans, Hypertension, Pulmonary, Male, Middle Aged, Netherlands, Prospective Studies, Respiratory Function Tests, Risk Factors, Incidence, Logistic Models, Case-Control Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
